A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Phase of Trial: Phase III
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms PROSPER RCC
- 19 Dec 2018 Planned number of patients changed from 766 to 805.
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.